Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 3 study of peginterferon beta-1a versus Avonex in pediatric relapsing-remitting multiple sclerosis
MOH_2019-07-30_007272Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Apr 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Started Apr 2019; status: active, not recruiting.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2019-07-30_007272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-30_007272.